Drug Approval | December 27, 2022
MindRank gets USFDA clearance of IND application for MDR-001 for treatment of Type 2 diabetes
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
The project will generate and supply green energy to fulfill about 50% present consumption of the company
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Sanjeev is currently the Country President for AstraZeneca Malaysia
To focus on providing safer burn treatments for women and armed forces
He is a seasoned leader with 34 years of rich and diverse experience across geographies and consumer facing companies such as Xerox India and Bharti Airtel
As a result, Imago will become a subsidiary of Merck.
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio
Move to increase affordability and accessibility for heart failure patients across the country
Subscribe To Our Newsletter & Stay Updated
